Let’s build your next reimbursement model and country adaptation
Your innovative product deserves a strategic approach to demonstrate its potential across global markets. With advanced economic modeling techniques, you can effectively quantify its economic impact and value proposition, enabling you to make informed decisions on pricing and reimbursement strategies.
Whether your focus is oncology, vaccines, rare diseases or devices, you can leverage Parexel’s decades of experience in building early and global cost-effectiveness models. Our expertise can help you to adapt these models to different countries, enhancing your chances of successful reimbursement.
Benefit from our scientific rigor, cutting-edge modelling techniques, and the opportunity to publish groundbreaking research that establishes your products' value. Leveraging our advanced templates, processes, and automation, we focus on crafting optimal model structures and innovative solutions to complex data challenges. With more than 200 model adaptations delivered for approximately 40 global markets and successful submissions to major HTA agencies worldwide (including NICE, TLV, HAS, CAD, INESSS, SMC, and Infarmed), our team ensures rapid return-on-investment in HEOR.
+
Global models developed internally
+
Model adaptations delivered for approximately 40 global markets
Think early, think strategically
From Phase II, our modelling team supports your strategic decisions with early economic models and HTA-ready analyses. We help you drive evidence generation plans, define your product’s value and engage effectively with clinical experts and key opinion leaders.
Although EU Joint Scientific Consultations (JCA) do not require cost-effectiveness models, we recommend this as an opportunity to test modelling assumptions, collect feedback from many EU states and experts at once, and prepare for an effective model submission.
Integration from early models to managed-entry agreements
Part of Access Consulting, the HEOR/Modelling team offers comprehensive support throughout your product’s lifecycle. We collaborate early with other key components of your reimbursement strategy, from initial economic evaluations to dossier submissions and HTA meetings.
We enhance your market potential by:
- Identifying key value drivers
- Guiding go/no-go decisions, optimizing resource allocation, and prioritizing investments with data-driven insights
- Informing early market access planning
- Conducting scenario analyses
- Optimizing trial design through key endpoint, patient population and comparator selection for clinical and economic evaluation
- Guiding evidence generation
- Developing differentiation strategies based on existing and pipeline competitors (particularly valuable in crowded therapeutic areas)
- Facilitating stakeholder discussions and alignment of internal expectations through early economic models
- Supporting regulatory submissions
- Providing a framework for ongoing assessment, long-term planning and lifecycle management
We understand that Managed Entry Agreements (MEAs) are crucial tools for addressing HTA uncertainties. Our expertise in this area spans diverse MEA types, from financial arrangements to performance/outcome-based agreements at both patient and population levels – adaptable across various countries.
We guide biopharma companies in leveraging MEAs to secure market access, maintain competitiveness and manage pricing strategies. By systematically analyzing the value and risks of different MEA options, we help clients navigate the complex decision-making process, balancing potential benefits against challenges to ensure optimal outcomes in the evolving market access landscape.
R and R-Shiny expertise
All our models are developed in MS Excel or R, with efficient templates, innovative use of AI, with our modellers-in-the-loop, and stringent quality control (QC).
We are at the forefront of developing sophisticated R/Shiny web applications tailored for HEOR, market access, and value communications. Our expertise in R programming allows us to create customizable models with advanced functionalities, ensuring rapid prototyping and iterative development to meet specific client needs. We integrate third-party libraries such as ggplot2, BCEA, parallel, and flexsurv for enhanced functionality.
We offer interactive applications that present complex calculations and results effectively, empowering economic modelling with customizable data visualization. Our global cost-effectiveness model template in R provides a standardized yet flexible framework, accelerating model development across various healthcare systems and therapeutic areas. With user-friendly interfaces, integrated sensitivity analysis tools, and multi-country adaptation features, we deliver robust, accessible solutions that combine Excel's ease of use with R's powerful analytics.
With Parexel's HEOR Modelling team, you're equipped to navigate the complex landscape of drug development with confidence, maximizing your product's chances of success from early stages through to market launch and beyond. Please get in touch, we’re always available for a conversation.